Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey
Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey
复制标题
DOI：
10.1183/09031936.97.10081795
复制
发表时间：
1997-08-01
影响因子：
24.3
通讯作者：
Burney, P
中科院分区：
文献类型：
--
作者：
Janson, C;Chinn, S;Burney, P
该分析的目的是估计医生诊断的哮喘患病率和年轻人哮喘治疗实践的地理差异，结果基于对14个国家34个中心的生态分析，其中随机选择的17,029名受试者（52%为女性，年龄20-48岁）进行了结构化访谈和肺活量测定，作为欧洲共同体呼吸健康调查的一部分。在调查医生诊断的哮喘患者的治疗时，样本中增加了2903名有症状的受试者。医生诊断的哮喘患病率最高的是新西兰和澳大利亚（11-13%），最低的是德国埃尔福特（1.2%）和西班牙（1.5-3.0%）。报告的抗哮喘药物在过去12个月内的使用也最高的是新西兰和澳大利亚（12-16%），并与诊断的哮喘患病率密切相关（r=0.89, p . 391）
The aim of this analysis was to estimate the geographical variation in the prevalence of physician-diagnosed asthma and treatment practice for asthma in young adults,The results are based on an ecological analysis of 34 centres in 14 countries, in which a total of 17,029 randomly selected subjects (52% females, age 20-48 yrs) underwent a structured interview and spirometry as part of the European Community Respiratory Health Survey, The sample was enriched with 2,903 symptomatic subjects when investigating treatment in subjects with physician-diagnosed asthma.The prevalence of physician-diagnosed asthma was highest in New Zealand and Australia (11-13%) and lowest in Erfurt, Germany (1.2%) and Spain (1.5-3.0%), The reported use of antiasthma medication in the last 12 months was also highest in New Zealand and Australia (12-16%) and correlated closely with the prevalence of diagnosed asthma (r=0.89, p